Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT02910557
Recruiting
A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.
Gender:
ALL
Ages:
All
Trial Updated:
07/10/2025
Locations: Corazon United States of America, LLC doing business as Life Clinical Trials, Coral Springs, Florida +22 locations
Conditions: Melanoma, Herpetic Infection
Register for Updates
Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
NCT03207854
Recruiting
This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/10/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Healthy Subject, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm, Immune System Disorder, Malignant Neoplasm
Register for Updates
Virtual Reality Attention Management
NCT03221244
Recruiting
Problems with distraction are widespread in the 21st century, but for people with developmental delays or behavioral challenges they can have more damaging effects. For example, susceptibility to distraction is associated with worse school and social performance, lower high school graduation rates, and increased incidence of serious accidents. The investigators' goal is to improve understanding of distractibility and develop a targeted treatment. The proposed intervention is based on models of h... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
07/10/2025
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: ADHD
Register for Updates
Shaping Tolerance for Delayed Rewards
NCT03457402
Recruiting
Deficits in self-control are of major public health relevance as they contribute to several negative outcomes for both individuals and society. For children, developing self-control is a critically important step toward success in academic settings and social relationships, yet there are few non-pharmacological approaches that have been successful in increasing self-control. We found in our earlier studies that self-control can be increased in preschool-aged children with high impulsivity by usi... Read More
Gender:
ALL
Ages:
Between 3 years and 6 years
Trial Updated:
07/10/2025
Locations: UC Davis MIND Institute, Sacramento, California
Conditions: Impulsivity
Register for Updates
Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures
NCT03568292
Recruiting
This trial studies how well virtual reality (VR) works in reducing pain and anxiety in cancer participants undergoing bone marrow biopsy or lumbar puncture. Virtual reality may impact pain and anxiety during and after the procedure.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/10/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Malignant Neoplasm
Register for Updates
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
NCT03858205
Recruiting
This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: City of Hope, Duarte, California +8 locations
Conditions: Bone Pain, Metastatic Malignant Neoplasm in the Bone, Plasma Cell Myeloma
Register for Updates
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT03995082
Recruiting
The purpose of this research protocol is to measure Patient Reported Outcome Measures (PROMs) in breast cancer patients. PROM results will be provided to patients and providers and the investigators will evaluate the relationship between patient engagement with PROM results and patient and clinicopathologic variables, utilization of supportive and hospital services, and patient satisfaction with patient-provider communication.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/10/2025
Locations: University of Colorado Hospital, Denver, Colorado +2 locations
Conditions: Breast Cancer
Register for Updates
Vaginal Microbiota Transplant
NCT04046900
Recruiting
This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial vaginosis.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
07/10/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Recurrent Bacterial Vaginosis
Register for Updates
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070
Recruiting
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +38 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Alabama At Birmingham, Birmingham, Alabama +51 locations
Conditions: Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, ET (Essential Thrombocythemia)
Register for Updates
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
Recruiting
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: University of California, San Diego (UCSD), San Diego, California +5 locations
Conditions: Castration Resistant Metastatic Prostate Cancer
Register for Updates
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
NCT04375384
Recruiting
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
Register for Updates